Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.11.18 (
MAP
)
7,412
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MAPK pathways transduce a broad variety of extracellular signals into cellular responses. Despite their pleiotropic effects and their ubiquitous distribution, surprisingly little is known about their involvement in the communication network of nerve cells. As a first step to elucidate the role of MAPK pathways in neuronal signalling, we studied the distribution of SAPK alpha/JNK2, SAPK beta/
JNK3
, and SAPK gamma/JNK1, three isoforms of SAPK/JNK, a stress-activated MAPK subfamily. We compared the mRNA localisation of the three main isoforms in the adult and developing rat brain using in situ hybridisation. In the adult brain, SAPK alpha and beta were widely but heterogeneously distributed, reproducing the pattern of a probe that does not discriminate the isoforms. Differently, high labelling for the SAPK gamma probe was exclusively localised in the endopiriform nucleus and medial habenula. Intermediate staining was detected in the hippocampus. During post-natal development, SAPK beta showed the same localisation as in the adult. Nevertheless, the semi-quantitative analysis of optical densities showed significantly different mRNA levels. In the adult, SAPK gamma signal was weak, whereas in newborn rats the labelling was intense and widely distributed. SAPK gamma mRNA levels decreased during development, to reach the low signals detected in the adult. These results suggest that in the central nervous system SAPK-type
MAP
kinases perform significant physiological functions which are particularly relevant during post-natal development. The distinct distribution patterns of SAPK isoforms in the adult rat brain support the hypothesis that separate functions are performed by the products of the three SAPK genes.
...
PMID:Differential expression of SAPK isoforms in the rat brain. An in situ hybridisation study in the adult rat brain and during post-natal development. 974 3
Activated p38gamma MAP kinase exhibited significant basal ATPase activity in the absence of a kinase substrate, and addition of a phosphoacceptor substrate increased k(cat)/K(m)20-fold. AMP-PCP was competitive with ATP binding and non-competitive with phosphoacceptor substrate binding. The nucleotide binding site affinity label 5'-(p-fluorosulfonylbenzoyl)adenosine (FSBA) bound stoichiometrically at Lys-56 in the ATP site of both unphosphorylated and activated p38gamma. AMP-PCP only protected the activated enzyme from FSBA inactivation, implying that AMP-PCP does not bind unphosphorylated p38gamma. Basal ATPase activities were also observed for activated p38alpha, ERK2 and
JNK3
suggesting that the enzymatic mechanism may be similar for all classes of
MAP
kinases.
...
PMID:Kinetic mechanism and ATP-binding site reactivity of p38gamma MAP kinase. 1056 20
There are at least three distinct MAP kinase signaling modules in mammalian cells, distinguished by the family of kinases (Erk, SAPK/JNK, or p38) that is ultimately activated. Many input signals activate multiple MAP kinase cascades, and the mechanisms that control the specificity of signal output are not well understood. We show that SEK1/MKK4, a MAP kinase kinase proposed to activate SAPK/JNK, is a very potent inhibitor of p54 SAPK beta/
JNK3
both in vitro and in vivo if present at equimolar or higher ratios. In contrast SEK can activate SAPK when present in substoichiometric amounts, but this activation is slow, consistent with the rate-limiting step in activation being the dissociation of an inactive SEK:SAPK complex. The N-terminal unique region of SEK is both necessary and partially sufficient for inhibition of SAPK, and is also necessary for activation of SAPK by SEK in vitro. We have also used the p38 MAP kinase and its activator MKK6 to examine the regulatory relationships among different kinases involved in stress responses. We show using purified kinases that inhibitory activity is specific for the combination of SEK and SAPK: SEK can activate but not inhibit p38, and MKK6 can activate but not inhibit SAPK beta and p38. These results reveal a potential mechanism for regulating stress-activated kinases, adding to a growing body of evidence suggesting that
MAP
kinases are controlled by relatively stable interactions with their activators.
...
PMID:Concentration-dependent positive and negative regulation of a MAP kinase by a MAP kinase kinase. 1059 70
JNK3
alpha 1 is predominantly a neuronal specific MAP kinase that is believed to require, like all
MAP
kinases, both threonine and tyrosine phosphorylation for maximal enzyme activity. In this study we investigated the in vitro activation of
JNK3
alpha 1 by MAP kinase kinase 4 (MKK4), MAP kinase kinase 7 (MKK7), and the combination of MKK4 + MKK7. Mass spectral analysis showed that MKK7 was capable of monophosphorylating
JNK3
alpha 1 in vitro, whereas both MKK4 and MKK7 were required for bisphosphorylation and maximal enzyme activity. Measuring catalysis under Vmax conditions showed MKK4 + MKK7-activated
JNK3
alpha 1 had Vmax 715-fold greater than nonactivated
JNK3
alpha 1 and MKK7-activated
JNK3
alpha 1 had Vmax 250-fold greater than nonactivated
JNK3
alpha 1. In contrast, MKK4-activated
JNK3
alpha 1 had no increase in Vmax compared to nonactivated levels and had no phosphorylation on the basis of mass spectrometry. These data suggest that MKK7 was largely responsible for
JNK3
alpha 1 activation and that a single threonine phosphorylation may be all that is needed for
JNK3
alpha 1 to be active. The steady-state rate constants kcat, Km(GST-ATF2++), and Km(ATP) for both monophosphorylated and bisphosphorylated
JNK3
alpha 1 were within 2-fold between the two enzyme forms, suggesting the addition of tyrosine phosphorylation does not affect the binding of ATF2, ATP, or maximal turnover. Finally, the MAP kinase inhibitor, SB203580, had an IC50 value approximately 4-fold more potent on the monophosphorylated
JNK3
alpha 1 compared to the bisphosphorylated
JNK3
alpha 1, suggesting only a modest effect of tyrosine phosphorylation on inhibitor binding.
...
PMID:Activation of JNK3 alpha 1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3 alpha 1. 1071 36
beta-arrestins play previously unsuspected and important roles as adapters and scaffolds that localize signaling proteins to ligand-activated G-protein-coupled receptors. As with the paradigmatic role of the beta-arrestins in uncoupling receptors from G proteins (desensitization), these novel functions involve the interaction of beta-arrestin with phosphorylated heptahelical receptors. beta-arrestins interact with at least two main classes of signaling proteins. First, interaction with molecules such as clathrin, AP-2 and NSF directs the clathrin-mediated internalization of G-protein-coupled receptors. Second, interaction with molecules such as Src, Raf, Erk, ASK1 and
JNK3
appears to regulate several pathways that result in the activation of
MAP
kinases. These recent discoveries indicate that the beta-arrestins play widespread roles as scaffolds and/or adapter molecules that organize a variety of complex signaling pathways emanating from heptahelical receptors. It is likely that additional roles for the beta-arrestins remain to be discovered.
...
PMID:Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. 1124 46
Primary cultures of rat cerebellar neurons were used to study mechanisms of arsenic neurotoxicity. Exposure to 5, 10, or 15 microM sodium arsenite reduced cerebellar neuron viability and induced nuclear fragmentation and condensation as well as DNA degradation to oligonucleosome fragments. Exposure to 1 or 5 mM dimethylarsinic acid caused similar changes. Therefore, both inorganic arsenite and organic dimethylarsinic acid induce apoptosis in cerebellar neurons, with the inorganic form being more toxic. Cotreatment with cycloheximide or actinomycin D, inhibitors of protein or RNA synthesis, respectively, or with the caspase inhibitor zVAD, completely blocked arsenite-induced cerebellar neuron apoptosis. This implies that arsenite-induced cerebellar neuron apoptosis requires new gene expression and caspase activation. Interestingly, sodium arsenite selectively activated p38 and
JNK3
, but not JNK1 or JNK2 in cerebellar neurons. Blocking the p38 or JNK signaling pathways using the inhibitors SB203580 or CEP-1347 protected cerebellar neurons against arsenite-induced apoptosis. These data suggest that arsenite neurotoxicity may be due to apoptosis caused by activation of p38 and
JNK3
MAP
kinases.
...
PMID:Arsenic induces apoptosis in rat cerebellar neurons via activation of JNK3 and p38 MAP kinases. 1144 28
beta-Arrestins are versatile adapter proteins that form complexes with most G-protein-coupled receptors (GPCRs) following agonist binding and phosphorylation of receptors by G-protein-coupled receptor kinases (GRKs). They play a central role in the interrelated processes of homologous desensitization and GPCR sequestration, which lead to the termination of G protein activation. beta-arrestin binding to GPCRs both uncouples receptors from heterotrimeric G proteins and targets them to clathrin-coated pits for endocytosis. Recent data suggest that beta-arrestins also function as GPCR signal transducers. They can form complexes with several signaling proteins, including Src family tyrosine kinases and components of the ERK1/2 and
JNK3
MAP kinase cascades. By recruiting these kinases to agonist-occupied GPCRs, beta-arrestins confer distinct signaling activities upon the receptor. beta-arrestin-Src complexes have been proposed to modulate GPCR endocytosis, to trigger ERK1/2 activation and to mediate neutrophil degranulation. By acting as scaffolds for the ERK1/2 and
JNK3
cascades, beta-arrestins both facilitate GPCR-stimulated MAP kinase activation and target active
MAP
kinases to specific locations within the cell. Thus, their binding to GPCRs might initiate a second wave of signaling and represent a novel mechanism of GPCR signal transduction.
...
PMID:The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. 1186 53
The c-Jun N-terminal kinases (JNKs) are important mediators of neurodegeneration and their actions include the activation of genetic programs by phosphorylation of the nuclear transcription factor c-Jun/AP-1, the release of cytochrome c or the pro-inflammatory actions of microglia. Recent data, however, provide evidence for physiological functions of JNKs in particular JNK1, and this involves a role of JNKs in the development of the brain and the (functional and/or structural) integrity of the cytoskeleton. Here we summarize our findings on the cytoskeleton-associated actions of JNKs. Thus, JNKs the relevant
MAP
kinases for the NGF-induced formation and elongation of PC12 cells, and this process is also supported by JNK2 and
JNK3
which are commonly considered as pro-apoptotic signal transducers. Importantly,
JNK3
is also mandatory for the intact differentiation of neurons since the functional deletion of
JNK3
caused apoptotic features such as activation of caspase 3 in untreated P0 primary hippocampal neurons and following glutamate excitotoxicity. Finally, we can visualize the presence of JNKs at the cytoskeleton, axon and growth cones of primary hippocampal neurons and PC12 cells, and this pattern changes following excitatory stimulation with glutamate. Thus, the functional role of JNKs during development and differentiation substantially differs from their degenerative actions in the adult brain.
...
PMID:c-Jun N-terminal kinases (JNKs) and the cytoskeleton--functions beyond neurodegeneration. 1546 86
c-Jun N-terminal kinases (JNKs), a family of
MAP
kinases, are central mediators of apoptosis and neurodegeneration, but also of plasticity and regeneration. Current concepts suggest that the compartmentalisation i.e. the distribution within cellular organelles and structures rather than substrate affinity determines the pathological and physiological function of individual JNKs. In contrast to JNK mediated activation of pro-apoptotic Bcl-2/BH3-only substrates, findings on the presence and activation of JNK isoforms in mitochondria are rare. Here we have analysed the specific localisation and activation of JNK1, JNK2 and
JNK3
as well as of their upstream MKK4/7 in brain mitochondria following transient middle cerebral artery occlusion (MCAo). The mitochondrial preparations were free of cytoskeletal, nuclear and ER contaminations, the specificity of antibodies was demonstrated in brain mitochondria from JNK deficient untreated mice. All JNKs were present in mitochondria with JNK1 as the major carrier of a strong basal JNK activity. Surprisingly, JNK activity was hardly detectable in the remaining cytoplasm. Between 2 and 18 h following MCAo, the pattern of JNK isoforms in mitochondria completely changed. Presence and activation of JNK1 almost completely disappeared. In striking contrast, presence and activation of JNK2 and, even more pronounced, of
JNK3
substantially increased. At the level of the upstream MKKs, complexes of MKK4:JNK1 were diminished, whereas complexes of
JNK3
with MKK4 and MKK7 were enhanced. These data strongly suggest that the basal physiological JNK1 activity is replaced in mitochondria by activated JNK2 and
JNK3
following neurodegenerative events. This pattern of "JNK1 goes and
JNK3
comes" might be essential for the initiation of apoptosis and suggests the search for targets of compartment-specific neuroprotective strategies.
...
PMID:Cerebral ischemia provokes a profound exchange of activated JNK isoforms in brain mitochondria. 1928 69
From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related
MAP
kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK inhibitors that retain favorable solubility, permeability, and P-gp properties for development as CNS agents for treatment of neurodegeneration. Compound 61 demonstrated
JNK3
IC(50)=77 nM and retained the excellent broad kinase selectivity observed for the series.
...
PMID:Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. 2107 Dec 23
1
2
Next >>